


A PROCESS FOR THE PREPARATION OF PHENYLTETRAZOLE DERIVATIVES

FIELD OF THE INVENTION

The present invention relates to a process for the preparation of substituted phenyltetrazole compounds, useful as intermediates for the preparation of angiotensin II antagonists.

BACKGROUND OF THE INVENTION

Angiotensin II antagonists are used, for example, in the treatment of hypertension, anxiety, glaucoma and heart failure. A number of these compounds are characterized by a biphenyltetrazole moiety and can be represented by the following formula (I)



wherein Z is an optionally substituted heterocycle containing at least one nitrogen atom; or an amido residue.

Preferably, the residue Z has the following meanings, which identify specific angiotensin II antagonists:

2-butyl-4-chloro-5-hydroxymethyl-imidazol-1-yl (losartan);


2-ethoxy-7-carboxy-1H-benzimidazol-1-yl (candesartan);

2-butyl-1,3-diaza-spiro[4,4]non-1-en-4-on-3-yl (irbesartan); and

(S)-N-(1-carboxy-2-methylprop-1-yl)-N-pentanoylamino (valsartan).

Key intermediates for the preparation of compounds of formula (I) are


2-substituted phenyltetrazoles of formula (II)



in which R is hydrogen, a protecting group or a salifying group and Y is
5 a $-B(OR_4)_2$ group, wherein each R_4 is independently hydrogen or C_1-C_6 alkyl;
or a ZnX group, wherein X is a halogen atom selected from chlorine, bromine
and iodine.


A number of processes for the preparation of the compounds of formula
(II) are known. For example, the process disclosed in US 5,039,814 or in
10 WO 93/10106 comprises the ortho-litiation of the phenyltetrazole and the
subsequent transmetallation reaction. The main drawbacks of said process
resides in the need to use an organo-lithium compound, i.e. a compound which
requires specific safety precautions when used on an industrial scale, due to its
high flammability and reactivity.

15 WO 99/01459 partly solves the problems deriving from the use of
organo-lithium compounds by reacting a compound of formula (III)



in which R is as defined above,

20 with a Grignard reagent of formula




in which R_1 is C_1 - C_6 alkyl or benzyl and X is as defined above;

in the presence of catalytic amounts of a secondary amine, which acts as a disaggregant of the Grignard reagent;

thereby obtaining a compound of formula (IV)

5



(IV)

wherein R and X are as defined above. This compound is however hardly reactive and cannot be used as such in "cross-coupling" reactions for the preparation of compounds of formula (I). Therefore, this compound is subjected to a transmetallation reaction, according to known procedures, to obtain a compound of formula (II) as defined above, which is much more reactive. The use of a Grignard reagent, compared with an organo-lithium compound, is undoubtedly safer, but still potentially dangerous on an industrial scale and still requires specific procedures.


It is therefore evident that there is still need for an alternative process for the preparation of compounds of formula (II), in particular a process which does not require the use of Grignard reagents.

DETAILED DESCRIPTION OF THE INVENTION

It has now been found a process for the preparation of compounds of formula (II) which does not involve the use of Grignard reagents and is therefore safer; furthermore, this process is more advantageous from the industrial point of view as it provides higher yields, is less costly and involves less preparation steps.


Therefore, the present invention relates to a process for the preparation

of compounds of formula (II)




wherein R is hydrogen, a protecting group or a salifying group and Y is
 5 a $-B(OR_4)_2$ group, in which each R_4 is independently hydrogen or C_1 - C_6 alkyl;
 or a $-ZnX$ group, wherein X is a halogen atom selected from chlorine, bromine
 and iodine;

which comprises the reaction of a compound of formula (V)




wherein R is as defined above and R_2 and R_3 , which can be the same or
 different, are straight or branched C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, trialkylsilyl,
 or R_2 and R_3 , taken together with the nitrogen atom they are linked to, form a
 saturated, optionally substituted, heterocyclic ring, containing one to two
 15 further heteroatoms independently selected from nitrogen, oxygen and sulfur;

either with a compound of formula (VI)



wherein X is as defined above;

or with a compound of formula (VIa)



wherein each R'_4 is independently C_1 - C_6 alkyl,

and, if desired, the subsequent hydrolysis of the resulting boronic ester of formula (II).

The term "protecting group R" means a tetrazole ring protecting group known in the art, preferably a straight or branched C₁-C₆ alkyl, optionally substituted with one or more phenyl groups, in their turn optionally substituted, for example with C₁-C₄ alkoxy or C₁-C₄ alkylthio. Preferred examples of R are tert-butyl, para-methoxybenzyl, trityl and 1-methyl-1-phenylethyl, the latter being particularly preferred.

The term "salifying group R" means, for example, an alkali or alkaline-earth metal, preferably sodium, potassium or magnesium, more preferably sodium.

When R₂ and R₃ are C₁-C₆ alkyl groups, they are preferably C₃-C₆ alkyl groups, more preferably isopropyl, sec-butyl, tert-butyl, most preferably isopropyl.

When R₂ and R₃ are C₃-C₆ cycloalkyl groups, they are preferably cyclopentyl and cyclohexyl.

When R₂ and R₃ are trialkylsilyl groups, they are preferably trimethylsilyl.

When R₄ is a C₁-C₆ alkyl group, it is preferably a straight or branched C₁-C₄ alkyl group, more preferably methyl, ethyl propyl, isopropyl, sec-butyl, tert-butyl, most preferably methyl, ethyl or isopropyl.

The term "heterocyclic ring" as defined above preferably means piperidine, piperazine, morpholine, pyrrolidine, more preferably 2,2,6,6-tetramethylpiperidine.

The reaction of a compound of formula (V) with a compound of formula (VI) or (VIa) is typically carried out in an ether solvent, preferably ethyl ether, dioxane, methyl tert-butyl ether, tetrahydrofuran or mixtures thereof, or mixtures thereof with apolar solvents, preferably hexane, heptane,

cyclohexane, benzene, toluene and xylene, more preferably tetrahydrofuran. The stoichiometric ratio of a compound of formula (VI) or (VIa) to a compound of formula (V) ranges from approx. 1.0 to approx. 5.0, preferably from 1.1 to 3.0. The reaction is carried out at a temperature ranging from about 20°C to the reflux temperature of the reaction mixture. Reaction times depend on the temperature and the progress of the reaction is monitored by conventional analytical methods.

The hydrolysis of a boronic ester of formula (II) to obtain a corresponding compound of formula (II) in which R₄ is hydrogen, can be carried out according to known methods, for example by addition of a mineral or organic acid, in particular phosphoric, hydrochloric or acetic acid, to the reaction mixture.

The compounds of formula (II) wherein R is a 1-methyl-1-phenyl-ethyl group and Y is a -B(OR₄)₂ group, in which R₄ is as defined above, are novel and are a further object of the invention.

Preferred examples are those in which each R₄ is independently hydrogen, methyl, ethyl or isopropyl.

Particularly preferred are the following compounds:

- 2-[2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl]-phenylboronic acid;
- 2-[2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl]-phenylboronic acid methyl ester; and
- 2-[2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl]-phenylboronic acid isopropyl ester.

The compounds of formula (V) are novel and are a further object of the present invention.

Preferred examples of compounds of formula (V) are:


- 2-[2-t-butyl-2H-tetrazol-5-yl]-phenyl magnesium diisopropylamide;
- 2-[2-sodium-2H-tetrazol-5-yl]-phenyl magnesium diisopropylamide;

and

- 2-[2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl]-phenyl magnesium diisopropylamide,

in particular the latter.


5 Compounds (V) can be prepared by reaction of compounds of formula (III)



(III)

wherein R is as defined above,

10 with compounds of formula (VII)



wherein R_2 and R_3 are as defined above.

The reaction between a compound of formula (III) and a compound of formula (VII) is typically carried out in an ether solvent, for example ethyl ether, dioxane, methyl tert-butyl ether, tetrahydrofuran or mixtures thereof, or mixtures thereof with apolar solvents, preferably hexane, heptane, cyclohexane, benzene, toluene and xylene, more preferably tetrahydrofuran. The stoichiometric ratio of a compound of formula (VII) to a compound of formula (III) ranges from approx. 0.5 to approx. 3.0, preferably from 1.0 to 2.0. The reaction is carried out at a temperature ranging from about 20°C to the reflux temperature of the reaction mixture, preferably at the reflux temperature. Reaction times depend on the temperature, and the progress of the reaction is monitored by conventional analytical methods. The resulting


15

20

compound of formula (V), which can optionally be isolated, is then reacted with a compound of formula (VI) or (VIa).

The compounds of formula (VII) can be obtained according to known processes, for example as described in DE 100 61 317. Preferably, the resulting compounds of formula (VII) are reacted with compounds of formula (III) without being isolated.

A further object of the invention is the use of a compound of formula (V) for the preparation of a compound of formula (I)



or a pharmaceutically acceptable salt thereof, in which Z is an optionally substituted heterocycle, containing at least one nitrogen atom; or an amido residue.

Preferably, a compound of formula (V) is used for the preparation of a compound of formula (I) in which Z is selected from:

2-butyl-4-chloro-5-hydroxymethyl-imidazol-1-yl;

2-ethoxy-7-carboxy-1H-benzimidazol-1-yl;

2-butyl-1,3-diaza-spiro[4,4]non-1-en-4-on-3-yl and

(S)-N-(1-carboxy-2-methylprop-1-yl)-N-pentanoylamino,

most preferably 2-butyl-4-chloro-5-hydroxymethyl-imidazol-1-yl.

The preparation of a compound of formula (I) from a compound of formula (II) can be carried out for example according to EP 846117 or WO 95/32962.

The following examples further illustrate the invention.

Example 1: Preparation of 2-[2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl]-phenyl zinc chloride (II)

A mixture of 2-(1-methyl-1-phenyl-ethyl)-5-phenyl-2H-tetrazole (5.0 g; 20.3 mmoles) and magnesium diisopropylamide (0.75 M solution in THF; 40 ml) is refluxed for 3 hrs. The mixture is subsequently cooled and diluted with a zinc chloride solution (5.4 g; 40.0 mmoles) in THF (29 ml). The resulting mixture is refluxed for a further 2 hrs.

¹H-NMR analysis, after treatment with deuterated water, evidences a conversion to organo-zinc higher than 96%.

Example 2: Preparation of 2-[2-Trityl-2H-tetrazol-5-yl]-phenyl magnesium diisopropylamide (V)

A mixture of 1-trityl-5-phenyl-2H-tetrazole (7.9 g; 20.3 mmoles) and magnesium diisopropylamide (0.75 M solution in THF; 40 ml) is refluxed for 3 hrs.

¹H-NMR analysis, after treatment with deuterated water, evidences a 67% conversion to organo-magnesium.

Example 3: Preparation of 2-[2-t-butyl-2H-tetrazol-5-yl]-phenyl magnesium diisopropylamide (V)

A mixture of 1-t-butyl-5-phenyl-2H-tetrazole (4.1 g; 20.3 mmoles) and magnesium diisopropylamide (0.75 M solution in THF; 40 ml) is refluxed for 3 hrs.

¹H-NMR analysis, after treatment with deuterated water, evidences a 75% conversion to organo-magnesium.

Example 4: Preparation of 2-[2-sodium-2H-tetrazol-5-yl]-phenyl magnesium diisopropylamide (V)

A mixture of 5-phenyl-2H-tetrazole sodium salt (3.4 g; 20.3 mmoles) and magnesium diisopropylamide (0.75 M solution in THF; 40 ml) is refluxed for 3 hrs.

¹H-NMR analysis, after treatment with deuterated water, evidences a 75% conversion to organo-magnesium.

Example 5: Preparation of 2-(2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl)-phenyl)-magnesium isopropylamide (V)

5 A 2 liters reactor is loaded with 600 ml of a magnesium diisopropylamide 0.75 M solution and 100 g of 2-(1-methyl-1-phenyl-ethyl)-5-phenyl-2H-tetrazole. The mixture is refluxed for 4 hrs., then the reaction is seeded with 1 g of 2-(2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl)-phenyl)-magnesium isopropylamide and then refluxed for a further 16 hrs. The
10 resulting mixture is cooled to 20-30°C, filtered by suction under inert atmosphere, then washed with THF to afford 102 g 2-(2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl)-phenyl)-magnesium isopropylamide.

¹H NMR (CD₃OD), (δ, ppm): 8.15 (1H, m); 7.43 (3H, m); 7.31 (3H, m); 7.18 (2H, d); 2.91 (2H, set); 2.20 (6H, s); 1.02 (12H, d).

15 **Example 6: Preparation of 2-(2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl)-phenyl)-boronic acid (II)**

A 2 liters reactor is loaded with 102 g 2-(2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl)-phenyl)-magnesium isopropylamide and 250 ml of THF. The suspension is cooled to 0-5°C and added with 58.3 g of trimethylborate in 20
20 minutes. The mixture is then gradually heated to room temperature, left under stirring for at least 2 hrs., then diluted to pH 2.5-3 with phosphoric acid. The resulting solution is heated to 30-35°C and kept at this temperature for 2 hrs., then stirring is interrupted and the aqueous phase is discarded. 250 ml of water are added to the organic phase and the resulting mixture is concentrated under
25 vacuum to remove THF. The resulting mixture is diluted with 60 ml of toluene and left under stirring at room temperature for at least 3 hrs. The precipitated product is filtered and washed with water and toluene. After drying a 60°C under vacuum, 60 g of 2-(2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl)-

phenyl)-boronic acid are obtained.

¹H NMR (DMSO d₆), (δ, ppm): 8.00 (2H, s); 7.90 (1H, m); 7.48 (3H, m); 7.31 (3H, m); 7.18 (2H, d); 2.15 (6H, s).

Example 7: Preparation 2-(2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-

5 5-yl)-phenyl)-boronic acid methyl ester (II)

A 2 liters reactor is loaded with 102 g 2-(2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl)-phenyl)-magnesium isopropylamide and 250 ml of THF. The suspension is cooled to 0-5°C and added with 58.3 g of trimethylborate, in 20 minutes. The mixture is then gradually heated to room temperature, left under stirring for at least 2 hrs., then diluted with water and toluene. The aqueous phase is discarded and the organic phase is evaporated to a residue. 70 g of an oil consisting of 2-(2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl)-phenyl)-boronic acid methyl ester methyl ester.

¹H NMR (DMSO d₆), (δ, ppm): 7.90 (1H, m); 7.48 (3H, m); 7.31 (3H, m); 7.18 (2H, d); 3.17 (6H, s); 2.15 (6H, s).

Following the same procedure, 2-(2-(1-methyl-1-phenyl-ethyl)-2H-tetrazol-5-yl)-phenyl)-boronic acid isopropyl ester is obtained.